ArticleCancer immunology research2016
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Article in Cancer immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Article
- Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.Cancer immunology research · 2023Article
- PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer.Frontiers in immunology · 2023Article
- Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?Clinical hematology international · 2023Review
- Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma.Discover oncology · 2022Article
- Review
- VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.Journal for immunotherapy of cancer · 2021Article
- Review
- Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells.Molecular therapy. Methods & clinical development · 2021Article
- Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.Translational cancer research · 2020Review
- A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.Journal for immunotherapy of cancer · 2019Article
- CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.Blood · 2018Article
- Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression.Nature communications · 2018Article
- Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
CD20 is an attractive immunotherapy target for B-cell non-Hodgkin lymphomas, and adoptive transfer of T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD20 is a promising strategy. A theoretical limitation is that residual serum rituximab might block CAR binding to CD20 and thereby impede T cell-mediated anti-lymphoma responses. The activity of CD20 CAR-modified T cells in the presence of various concentrations of rituximab was tested in vitro and in vivo CAR-binding sites on CD20(+) tumor cells were blocked by rituximab in a dose-dependent fashion, although at 37°C blockade was incomplete at concentrations up to 200 μg/mL. T cells with CD20 CARs also exhibited modest dose-dependent reductions in cytokine secretion and cytotoxicity, but not proliferation, against lymphoma cell lines. At rituximab concentrations of 100 μg/mL, CAR T cells retained ≥50% of baseline activity against targets with high CD20 expression, but were more strongly inhibited when target cells expressed low CD20. In a murine xenograft model using a rituximab-refractory lymphoma cell line, rituximab did not impair CAR T-cell activity, and tumors were eradicated in >85% of mice. Clinical residual rituximab serum concentrations were measured in 103 lymphoma patients after rituximab therapy, with the median level found to be only 38 μg/mL (interquartile range, 19-72 μg/mL). Thus, despite modest functional impairment in vitro, the in vivo activity of CD20-targeted CAR T cells remains intact at clinically relevant levels of rituximab, making use of these T cells clinically feasible. Cancer Immunol Res; 4(6); 509-19. ©2016 AACR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.